Stockscreener 앱 받기
2.41
2.03%
-0.05
시간 외 거래:
2.41
전일 마감가:
$2.46
열려 있는:
$2.4528
하루 거래량:
19,895
Relative Volume:
0.17
시가총액:
$32.65M
수익:
-
순이익/손실:
$-81.21M
주가수익비율:
-0.3908
EPS:
-6.1668
순현금흐름:
$-61.42M
1주 성능:
+3.88%
1개월 성능:
-24.92%
6개월 성능:
+20.50%
1년 성능:
-55.78%
1일 변동 폭
$2.3501
$2.4528
1주일 범위
$2.30
$2.5899
52주 변동 폭
$1.70
$6.176
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.41 | 33.33M | 0 | -81.21M | -61.42M | -6.1668 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
EV Market: Should I set a stop loss on OnKure Therapeutics Inc2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Published on: 2026-01-29 15:39:37 - mfd.ru
Why OnKure Therapeutics Inc. stock could be next big winnerShort Interest Overview & High Yield Trading Alerts - bollywoodhelpline.com
Analyzing Nautilus Biotechnology (NASDAQ:NAUT) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts - Defense World
Published on: 2026-01-11 10:53:08 - Улправда
Targets Report: How risky is OnKure Therapeutics Inc stock nowEarnings Recap Summary & Weekly Sector Rotation Insights - Bộ Nội Vụ
How OnKure Therapeutics Inc. stock performs in weak economyEarnings Overview Report & Daily Market Momentum Tracking - Улправда
Geopolitics Watch: How risky is OnKure Therapeutics Inc. stock nowMarket Sentiment Review & Detailed Earnings Play Strategies - Улправда
Bear Alert: Will OnKure Therapeutics Inc stock attract ESG investorsFed Meeting & Weekly High Momentum Picks - Bộ Nội Vụ
Rally Mode: Why OnKure Therapeutics Inc. stock could be next big winnerJuly 2025 Snapshot & Safe Entry Trade Reports - Улправда
How OnKure Therapeutics Inc. stock performs after earnings - ulpravda.ru
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com India
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
OnKure Therapeutics CFO Leverone sells $896 in stock By Investing.com - Investing.com Canada
OnKure Therapeutics CFO Leverone sells $896 in stock - Investing.com
OnKure Therapeutics CEO Saccomano sells $258 in stock - Investing.com
Is OnKure Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Trade Execution Alerts - Улправда
Aug Technicals: What analyst consensus says on UYSCU stockJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Can OnKure Therapeutics Inc. stock sustain free cash flow growthWeekly Stock Recap & Precise Swing Trade Alerts - Улправда
Can OnKure Therapeutics Inc. stock rebound after recent weaknessWeekly Market Outlook & Free Community Consensus Stock Picks - Улправда
Why OnKure Therapeutics Inc. stock could rally in 2025Wall Street Watch & Weekly High Conviction Trade Ideas - Bölüm Sonu Canavarı
Why OnKure Therapeutics Inc. stock is considered a top pick2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Why OnKure Therapeutics Inc. stock is a must watch in 2025July 2025 Outlook & AI Forecasted Stock Moves - DonanımHaber
CEO Change: How OnKure Therapeutics Inc. stock performs in high volatility marketsMarket Volume Report & Capital Protection Trade Alerts - Улправда
Aug PostEarnings: Why OnKure Therapeutics Inc. stock is considered a top pickJuly 2025 Market Mood & Risk Managed Investment Signals - Улправда
Is OnKure Therapeutics Inc. stock a buy on dipsMarket Risk Summary & Accurate Intraday Trade Tips - Улправда
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) dropped from NASDAQ Biotechnology Index - marketscreener.com
OnKure Therapeutics Earnings Notes - Trefis
Acorn Capital Advisors LLC Grows Position in OnKure Therapeutics, Inc. $OKUR - Defense World
Why OnKure Therapeutics Inc stock could rally in 2025Weekly Volume Report & Reliable Entry Point Trade Alerts - moha.gov.vn
Ready to Jump After Recent Trade: OnKure Therapeutics Inc (OKUR) - Setenews
Why OnKure Therapeutics Inc. stock could outperform in 2025CPI Data & Weekly Breakout Stock Alerts - Newser
OnKure Therapeutics (OKUR) Stock Analysis Report | Financials & Insights - Benzinga
Will OnKure Therapeutics Inc. stock sustain high P E ratiosMarket Performance Recap & Capital Efficient Trade Techniques - Newser
Published on: 2025-11-27 20:24:24 - BỘ NỘI VỤ
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
[424B3] OnKure Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
What margin trends mean for OnKure Therapeutics Inc. stockGDP Growth & Weekly Chart Analysis and Guides - newser.com
Why OnKure Therapeutics Inc. stock is a value investor pickJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
Onkure Therapeutics Inc (OKUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Onkure Therapeutics Inc 주식 (OKUR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Dec 22 '25 |
Sale |
2.97 |
302 |
896 |
16,301 |
| Saccomano Nicholas A | President and CEO |
Sep 22 '25 |
Sale |
2.62 |
88 |
231 |
3,506 |
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
| Saccomano Nicholas A | President and CEO |
Jun 23 '25 |
Sale |
2.38 |
88 |
210 |
3,594 |
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
1.24%
0.19%
자본화:
|
볼륨(24시간):